[Erectile dysfunction: an update on new therapeutic options].
Roumeguère
T
T
Dienst Urologie, HU Erasme, Brussel, ULB.
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000368:Aged; D001058:Apomorphine / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D020030:Nitric Oxide Donors / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D018491:Dopamine Agonists; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D001058:Apomorphine